Report Highlights
The global market for liquid biopsy is expected to grow from $4.6 billion in 2024 and is projected to reach $13.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 23.3% during the forecast period of 2024 to 2029.
Report Includes
- 65 data tables and 58 additional tables
- Analyses of the trends in the global market for liquid biopsy research tools, services and diagnostics, with market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024, and projected CAGRs through 2029
- Estimates of the market size and revenue growth prospects, along with a market share analysis by application, purpose of analysis, biomarker type, analysis platform (technology type) and region
- Examination of conventional biopsy methods and liquid biopsy enabling technologies
- Discussion of large-scale research initiatives
- Facts and figures pertaining to key market dynamics, technology advances, regulations, and the impact of macroeconomic factors
- Insights derived from the Porter’s Five Forces model, as well as global supply chain and PESTLE analyses
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Patent analysis, including key granted and published patents
- Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of leading companies, including Exact Sciences Corp., Natera Inc., Guardant Health, Roche, and NeoGenomics Laboratories
Report Scope
This report provides an in-depth analysis of the global market for liquid biopsy tools, services and diagnostics, including market estimations and trends, using 2023 as the base year and forecasting 2024 through 2029 with a compound annual growth rate (CAGR) projection. The report includes an overview of the industry structure and its competitive landscape. Leading market players’ profiles, product offerings, financial information and recent market activities are provided. The report also assesses companies’ business strategies and their effect in the face of the competitive environment. It details the global market based on application, purpose of analysis, biomarker type and platform. Regional analysis includes North America (U.S., Canada, Mexico), Europe (U.K., Germany, France, Spain, Italy, Rest of Europe), Asia-Pacific (China, India, Japan, and Rest of Asia-Pacific), and the Rest of the world (South America, and the Middle East and Africa).
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Highlights
The global market for liquid biopsy should increase from $3.8 billion in 2020 to $19.6 billion by 2025, at a compound annual growth rate (CAGR) of 38.5% during the period of 2020-2025.
Report Includes
- 29 data tables and 56 additional tables
- An overview of the global market for liquid biopsy research tools, services and diagnostics
- Estimation of the market size and analyses of global market trends, with data from 2019 and 2020, and projections of compound annual growth rates (CAGRs) through 2025
- Characterization and quantification of market potential for liquid biopsy diagnostics by application, biomarker type, analysis platform, analysis purpose and geographical region
- Discussion on significant large-scale research initiatives that are contributing to liquid biopsy market development
- Examination of various conventional biopsy methods and information on how liquid biopsy enabling technologies address the issues and are gaining significant traction with key opinion leaders
- Identification of market drivers, restraints and other forces influencing the growth of the liquid biopsy market
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
- Review of patents and new developments in circulating tumor cell (CTC) technologies, exosome technologies, cell-free DNA technologies, and cancer biomarkers
- Company profiles of major liquid biopsy market players, including Bard1 Life Sciences Ltd., Becton, Dickinson and Co. (BD), Bio-Rad Laboratories Inc., Danaher Corp., Exosome Sciences Inc., Qiagen NV and Roche Holding AG
Report Highlights
The global liquid biopsy market should reach $6.1 billion by 2023 from $2.4 billion in 2018 at a compound annual growth rate (CAGR) of 20.8% for the period 2018 to 2023.
Report Includes
- 32 data tables and 54 additional tables
- Industry analysis of the liquid biopsy biomarkers and technologies market
- Analyses of global market trends with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Characterization and quantification of market potential for liquid biopsy diagnostics by application, biomarker type, analysis platform, analysis purpose and geographical region
- Discussion of several significant large-scale research initiatives that are contributing to liquid biopsy market development
- Examination of various conventional biopsy methods and highlight how liquid biopsy enabling technologies address the issues and are gaining significant traction with key opinion leaders
- Coverage of significant patents and their allotments in each category, as well as major industry acquisitions and strategic alliances data
- Company profiles of major manufacturers and suppliers of liquid biopsy research tools, services and diagnostics, including Agilent Technologies Inc., Cygnus Biosciences, Illumina Inc., Oxford Nanopore, Qiagen, Quantum Biosystems, Roche and Thermo Fisher Scientific
Report Highlights
The global liquid biopsy market should reach $4.5 billion by 2022 from $1.5 billion in 2017 at a compound annual growth rate (CAGR) of 24.2%, from 2017 to 2022.
Report Includes
- An overview of the global markets for liquid biopsy research tools, services, and diagnostics
- Analyses of global market trends, with data from 2015 and 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Coverage of how these technologies can reduce invasive tumor biopsies, drive early cancer detection, and support precise drug administration
- Detailed analysis of liquid biopsy workflow technologies, biomarker classes, sample types, and research tools reagents
- Breakdowns of the market by product, product type, application, end use industry, technology, and indication
- Evaluation of the market's dynamics, specifically growth drivers, restraints, and opportunities
- Profiles of major players in the industry
Report Highlights
The global liquid biopsy market should reach nearly $4.5 billion in 2020 from $1.6 billion in 2015, registering a CAGR of 22.3% for the period of 2015-2020.
Report Includes
- An overview of the global markets for liquid biopsy research tools, services, and diagnostics
- Analyses of global market trends, with data for 2014, estimates for 2015, and projections of CAGRs through 2020
- Coverage of how these technologies can reduce invasive tumor biopsies, drive early cancer detection, and support precise drug administration
- Detailed analysis of liquid biopsy workflow technologies, biomarker classes, sample types, research tools reagents, and more
- Breakdowns of the market by product, product type, application, end use industry, technology, indication, as well as many others
- Evaluation of the market's dynamics, specifically growth drivers, restraints, and opportunities
- Profiles of major players in the industry
Related Reports
Exosome Diagnostics, Therapeutics and Research Tools: Global Markets
The global market for exosome diagnostics, therapeutics and research tools is estimated to increase from $227.5 million in 2023 to reach $1.3 billion by 2028, at a compound annual growth rate (CAGR) of 42.2% from 2023 through 2028.
Next-generation Sequencing: Emerging Clinical Applications and Global Markets
The global market for clinical applications of next-generation sequencing is estimated to increase from $21.9 billion in 2023 to reach $52.9 billion by 2028, at a compound annual growth rate (CAGR) of 19.3% from 2023 through 2028.
Oncology Biomarkers: Global Markets
The global oncology biomarkers market reached $15.5 billion in 2022, should reach $17.6 billion by 2023 and $35.2 billion by 2028 with a compound annual growth rate (CAGR) of 14.9% during the forecast period of 2023-2028.
Next-Generation Cancer Diagnostics: Technologies and Global Markets
The global next-generation cancer diagnostics market reached $8.7 billion in 2022 and should reach $15 billion by 2027, with a compound annual growth rate (CAGR) of 11.5% during the forecast period of 2022-2027.
Recent Reports
Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets
The global market for liquid biopsy is expected to grow from $4.6 billion in 2024 and is projected to reach $13.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 23.3% during the forecast period of 2024 to 2029.
Life Science Tools and Reagents: Global Markets
The global market for life science tools and reagents, including COVID-19 diagnostics was valued at $59.4 billion in 2023. This market is expected to grow from $53.2 billion in 2024 to reach $66.5 billion by the end of 2029, at a CAGR of 4.6% during the forecast period of 2024-2029.
RNAi Technologies and Global Markets
The global market for RNAi technology is estimated to increase from $2.1 billion in 2023 to reach $4.8 billion by 2029, at a compound annual growth rate (CAGR) of 14.8% from 2024 through 2029.
Metabolomics: Technologies and Global Markets
The global market for metabolomics technologies is expected to grow from $16.4 billion in 2024 and is projected to reach $30.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 13.1% during the forecast period of 2024 to 2029.
Global Recombinant Proteins Market
The global market for recombinant proteins is estimated to increase from $132.4 billion in 2023 to reach $203.6 billion by 2029, at a compound annual growth rate (CAGR) of 7.5% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More